Lantheus To Acquire Evergreen Theragnostics

Lantheus To Buy Evergreen Theragnostics For Over $1 Billion To Bolster Its Cancer Radiopharmaceutical Portfolio
Lantheus strengthens its radiopharmaceutical business with Evergreen and Life Molecular acquisitions, adding oncology and Alzheimer's diagnostics.
Lantheus to buy radiopharma CDMO Evergreen Theragnostics for $250M upfront
Lantheus Holdings is stepping up its game in the radiopharmaceutical space by acquiring Massachusetts-based Evergreen Theragnostics for $250 million upfront.
Lantheus’s Strategic Acquisition of Evergreen Theragnostics Strengthens Radiopharmaceutical Leadership and Growth Prospects
Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on LNTH stock, giving a Buy rating yesterday.Invest with Confidence:
Lantheus Holdings to Acquire Evergreen Theragnostics
Lantheus Holdings Inc., a radiopharmaceutical-focused company, has agreed to acquire Evergreen Theragnostics Inc., in an all-cash transaction consisting of an upfront payment of $250 million and up to an additional $752.5 million in potential milestone payments.
Lantheus acquires radiopharma CDMO Evergreen for up to $1bn
The deal includes an upfront payment of $250m, with the potential for an additional $752.5m in milestone payments.
Lantheus To Acquire Evergreen Theragnostics; Reaffirms Guidance
Lantheus Holdings (LNTH) announced a definitive agreement to acquire Evergreen Theragnostics, Inc. in an all-cash transaction
Lantheus to acquire Evergreen Theragnostics for $250M upfront
Lantheus (LNTH) announced a definitive agreement to acquire Evergreen Theragnostics in an all-cash transaction consisting of an upfront payment of
Outsourcing-pharma2d
Lantheus to acquire Evergreen in $1bn deal to expand radiopharmaceutical pipeline
Lantheus is acquiring radiopharmaceutical CDMO Evergreen Theragnostics in a deal worth up to $1 billion, expanding its manufacturing capabilities and drug pipeline. The acquisition includes Octevy, a ...
FiercePharma4d
Lantheus lays out $250M+ to get its hands on radiopharma developer and CDMO Evergreen
On a quest to carve out a spot as one of the nuclear medicine greats, Massachusetts-based radiopharmaceutical specialist ...
Lantheus expands in neuro and oncology with LMI and Evergreen acquisitions
Lantheus' oncology portfolio includes Pylarify (piflufolastat F 18) and a growing pipeline addressing various solid tumours.
Hosted on MSN2d
LNTH: Evergreen Acquisition Promotes Future Innovation
LNTH Lantheus to Buy Evergreen Theragnostics Lantheus Holdings, Inc. (NASDAQ:LNTH) announced its second acquisition this ...
Why Lantheus Holdings Stock Got Thrashed on Tuesday
Radiopharmaceutical specialist Lantheus Holdings (NASDAQ: LNTH) had some news to report Tuesday morning, but the market ...